Breaking Down SG&A Expenses: Catalent, Inc. vs Sarepta Therapeutics, Inc.

A Comparative Analysis of SG&A Expenses: Catalent, Inc. vs. Sarepta Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. Catalent, Inc. and Sarepta Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Catalent's SG&A expenses surged by approximately 180%, reflecting its aggressive expansion and operational scaling. In contrast, Sarepta's expenses increased by nearly 870%, indicating its rapid growth and investment in innovative therapies.

Catalent's expenses peaked in 2024, while Sarepta's data for the same year remains unavailable, highlighting potential reporting gaps. The data underscores Catalent's consistent growth strategy, while Sarepta's fluctuating expenses suggest a more volatile financial trajectory. This analysis provides a window into the strategic priorities of these pharmaceutical giants, offering valuable insights for investors and industry analysts alike.